Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tirofiban is a non-peptide selective glycoprotein (GP) IIb/IIIa receptor inhibitor that reversibly inhibits fibrinogen-dependent platelet aggregation and subsequent formation of thrombi. It is primarily used to prevent blood clots from forming in the arteries of the heart after certain types of chest pain and heart attacks. It may also be used in patients who are having certain heart and blood vessel procedures, particularly in non-ST elevated acute coronary syndrome. Tirofiban has a rapid onset and short duration of action after proper IV administration, with coagulation parameters returning to normal 4 to 8 hours after the drug is withdrawn. It is a synthetic, non-peptide inhibitor derived from a molecule found in the venom of the saw-scaled viper (Echis carinatus).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tirofiban.